PubRank

Mark S Cragg

Author PubWeight™ 56.19‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004 3.38
2 Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 2006 3.06
3 Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007 2.99
4 Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010 2.31
5 Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008 2.22
6 Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011 1.91
7 Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009 1.76
8 Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood 2013 1.58
9 Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 2011 1.44
10 CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003 1.40
11 Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2009 1.38
12 Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011 1.34
13 Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood 2010 1.19
14 Retracted STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. J Cell Sci 2005 1.17
15 Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J Immunol 2011 1.16
16 Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem 2008 1.15
17 CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010 1.12
18 Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012 1.09
19 Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. BMC Cancer 2006 1.05
20 Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. J Cell Sci 2003 1.02
21 Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int 2013 1.01
22 Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation. Cell Biol Int 2011 1.00
23 Cancer: a matter of life cycle? Cell Biol Int 2007 1.00
24 Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2008 0.98
25 Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res 2008 0.95
26 FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother 2013 0.90
27 Regulating the genome surveillance system: miRNAs and the p53 super family. Apoptosis 2010 0.89
28 Transforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas. J Biol Chem 2012 0.89
29 DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells. Cell Cycle 2012 0.88
30 The role of meiotic cohesin REC8 in chromosome segregation in gamma irradiation-induced endopolyploid tumour cells. Exp Cell Res 2009 0.87
31 Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98). Br J Haematol 2014 0.86
32 Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res 2013 0.85
33 Family friction as ΔNp73 antagonises p73 and p53. Int J Biochem Cell Biol 2011 0.84
34 B cells--masters of the immunoverse. Int J Biochem Cell Biol 2010 0.84
35 Functional analysis of HIV type 1 Nef reveals a role for PAK2 as a regulator of cell phenotype and function in the murine dendritic cell line, DC2.4. J Immunol 2005 0.81
36 CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. Exp Hematol 2012 0.80
37 Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization. J Immunol 2013 0.80
38 Apparent modulation of CD20 by rituximab: an alternative explanation. Blood 2004 0.80
39 Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B). Eur J Immunol 2012 0.80
40 Complement: help or hindrance? Blood 2009 0.79
41 Macroautophagy-aided elimination of chromatin: sorting of waste, sorting of fate? Autophagy 2012 0.79
42 Tumor cell embryonality and the ploidy number 32n: is it a developmental checkpoint? Cell Cycle 2011 0.77
43 FcγRIIB as a key determinant of agonistic antibody efficacy. Curr Top Microbiol Immunol 2014 0.77
44 The potential effect of statins on rituximab immunotherapy. PLoS Med 2008 0.77
45 Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 2003 0.76
46 Role of STAT1 in the breast. JAKSTAT 2012 0.76
47 Correction: Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus. PLoS One 2016 0.75
48 Rehabilitation or the death penalty: autoimmune B cells in the dock. Eur J Immunol 2015 0.75
49 Development of immunomonitoring of antibody‑dependent cellular cytotoxicity against neuroblastoma cells using whole blood. Cancer Immunol Immunother 2014 0.75